Related Experiment Video

Updated: Dec 19, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.0K

LncRNA AFAP1-AS1 contributes to the progression of endometrial carcinoma by regulating miR-545-3p/VEGFA pathway

Youwen Zhong1, Yidong Wang2, Huimin Dang3

  • 1School of Economics and Finance, Xi'an Jiaotong University, Xi'an City, Shaanxi Province, 710061, China.

Molecular and Cellular Probes
|June 7, 2020
PubMed

Insights

High expression of actin filamentin-1 antisense RNA 1 (AFAP1-AS1) promotes endometrial carcinoma (EC) growth and metastasis. AFAP1-AS1 may serve as a novel therapeutic target for EC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • RNA Biology

Background:

  • Endometrial carcinoma (EC) is a common gynecological malignancy.
  • Targeted therapies offer advantages but require identification of new therapeutic targets.
  • Long non-coding RNAs (lncRNAs) regulate cellular functions and are implicated in various cancers.

Purpose of the Study:

  • To investigate the role of lncRNA AFAP1-AS1 in endometrial carcinoma.
  • To elucidate the underlying regulatory mechanism of AFAP1-AS1 in EC progression.

Main Methods:

  • Analysis of AFAP1-AS1 expression in human EC tissues.
  • Assessment of AFAP1-AS1's impact on EC cell proliferation, migration, and invasion.
  • Investigation of AFAP1-AS1's effect on endothelial cell angiogenesis.
  • Determination of AFAP1-AS1's interaction with miR-545-3p and VEGFA expression.

Main Results:

  • AFAP1-AS1 was highly expressed in EC tissues and correlated with patient prognosis and clinical features.
  • AFAP1-AS1 promoted EC cell proliferation, migration, invasion, and angiogenesis.
  • AFAP1-AS1 upregulated VEGFA expression by adsorbing miR-545-3p.
  • AFAP1-AS1 facilitated tumor growth and metastasis in vivo.

Conclusions:

  • AFAP1-AS1 plays a significant role in endometrial carcinoma progression.
  • The AFAP1-AS1/miR-545-3p/VEGFA axis promotes EC angiogenesis, invasion, and metastasis.
  • AFAP1-AS1 represents a potential therapeutic target for endometrial carcinoma.
Keywords:
Actin filamentin-1 antisense RNA 1 (AFAP1-AS1)AngiogenesisEndometrial carcinoma (EC)InvasionProliferation

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.9K
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

17.9K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.6K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.6K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.2K